SEC Form 13F
| Report period | 2026-03-31 |
|---|---|
| Publicly available | 2026-05-13 |
| Reported value | $52,769,920 |
| Positions | 6 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Evommune, Inc. | EVMN | COM SHS | $29,445,086 | 1,280,778 |
| Inventiva S.A. | IVA | ADS | $13,064,700 | 2,354,000 |
| Wave Life Sciences Ltd. | WVE | SHS | $5,437,500 | 750,000 |
| Rani Therapeutics Holdings, Inc. | RANI | COM CL A | $2,694,941 | 3,667,585 |
| Clene Nanomedicine Inc. | CLNN | COM NEW | $2,125,293 | 431,094 |
| Surrozen, Inc. | Unresolved | *W EXP 08/01/203 | $2,400 | 150,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.